Carisma Therapeutics Net Worth
Carisma Therapeutics Net Worth Breakdown | CARM |
Carisma Therapeutics Net Worth Analysis
Carisma Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Carisma Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Carisma Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Carisma Therapeutics' net worth analysis. One common approach is to calculate Carisma Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Carisma Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Carisma Therapeutics' net worth. This approach calculates the present value of Carisma Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Carisma Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Carisma Therapeutics' net worth. This involves comparing Carisma Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Carisma Therapeutics' net worth relative to its peers.
To determine if Carisma Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Carisma Therapeutics' net worth research are outlined below:
| Carisma Therapeutics generated a negative expected return over the last 90 days | |
| Carisma Therapeutics has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 14.92 M. Net Loss for the year was (86.88 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Carisma Therapeutics generates negative cash flow from operations | |
| Carisma Therapeutics has a frail financial position based on the latest SEC disclosures | |
| About 29.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference |
Carisma Therapeutics Quarterly Good Will |
|
Carisma Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Carisma Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Carisma Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow Carisma Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 35.65 M.Market Cap |
|
Project Carisma Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.97) | (1.02) | |
| Return On Capital Employed | (1.20) | (1.27) | |
| Return On Assets | (0.97) | (1.02) | |
| Return On Equity | (3.27) | (3.11) |
When accessing Carisma Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Carisma Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Carisma Therapeutics' profitability and make more informed investment decisions.
Evaluate Carisma Therapeutics' management efficiency
Carisma Therapeutics has return on total asset (ROA) of (0.5608) % which means that it has lost $0.5608 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.6279) %, meaning that it created substantial loss on money invested by shareholders. Carisma Therapeutics' management efficiency ratios could be used to measure how well Carisma Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 2nd of December 2024, Return On Tangible Assets is likely to drop to -1.02. In addition to that, Return On Capital Employed is likely to drop to -1.27. At this time, Carisma Therapeutics' Non Currrent Assets Other are very stable compared to the past year. As of the 2nd of December 2024, Total Current Assets is likely to grow to about 84.5 M, while Total Assets are likely to drop about 65.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.79 | 0.83 | |
| Tangible Book Value Per Share | 0.79 | 0.75 | |
| Enterprise Value Over EBITDA | (0.28) | (0.29) | |
| Price Book Value Ratio | 3.70 | 3.89 | |
| Enterprise Value Multiple | (0.28) | (0.29) | |
| Price Fair Value | 3.70 | 3.89 | |
| Enterprise Value | 23.7 M | 16.4 M |
The strategic initiatives led by Carisma Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 0.5969 | Revenue 20.3 M | Quarterly Revenue Growth (0.12) | Revenue Per Share 0.493 | Return On Equity (3.63) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Carisma Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Carisma Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Carisma Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Carisma Therapeutics time-series forecasting models is one of many Carisma Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Carisma Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Carisma Therapeutics Earnings per Share Projection vs Actual
Carisma Therapeutics Corporate Management
| Terry Shields | Senior Resources | Profile | |
| Kenneth Locke | Senior Operations | Profile | |
| MD FACS | Chief Officer | Profile | |
| MBA JD | General Secretary | Profile | |
| Tom Wilton | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Carisma Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Carisma Therapeutics. If investors know Carisma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Carisma Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.493 | Quarterly Revenue Growth (0.12) | Return On Assets (0.56) | Return On Equity (3.63) |
The market value of Carisma Therapeutics is measured differently than its book value, which is the value of Carisma that is recorded on the company's balance sheet. Investors also form their own opinion of Carisma Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Carisma Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Carisma Therapeutics' market value can be influenced by many factors that don't directly affect Carisma Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Carisma Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Carisma Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Carisma Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.